CHAIN welcomes to its Board of Directors the recent appointment of Dr Mike McDonald and Peter McPartland as Non-Executive Directors. The appointments follow CHAIN’s successful seed investment round, led by Rainbow Seed Fund, earlier this year. Dr McDonald, a physician, brings 30 years of experience in US and European drug development. He has leadership and […]
CHAIN Biotechnology is proud to announce that it is a finalist in two competitions celebrating excellence in the fields of biotechnology and life sciences. CHAIN has made it to the final round of the OBN Awards for “Best Emerging UK Synthetic Biotech” and the Institute of Chemical Engineering (IChemE) Global Awards for “Best Business Start-Up”. […]
LONDON, UK, 10 AUGUST 2016 — CHAIN Biotechnology Ltd has successfully completed a 12-month research project entitled “Chiral Chemical Synthesis in Clostridia”. The research was supported by a grant from Innovate UK, the UK’s innovation agency. Specifically, CHAIN has demonstrated a new way to change the stereochemistry of intracellular metabolism in Clostridia bacteria, resulting in […]
CHAIN Biotechnology Ltd develops Clostridium-based microbial technology for high-value healthcare products. We produce novel 2nd generation live biotherapeutic products for chronic gut-related diseases.
CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD™ technology. Our lead product targets Inflammatory Bowel Disease.